当前位置: X-MOL 学术Expert Rev. Vaccines › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Recent advances in lipopolysaccharide-based glycoconjugate vaccines
Expert Review of Vaccines ( IF 6.2 ) Pub Date : 2021-10-25 , DOI: 10.1080/14760584.2021.1984889
Henderson Zhu 1 , Christine S Rollier 1 , Andrew J Pollard 1
Affiliation  

ABSTRACT

Introduction

The public health burden caused by pathogenic Gram-negative bacteria is increasingly prominent due to antimicrobial resistance. The surface carbohydrates are potential antigens for vaccines against Gram-negative bacteria. The enhanced immunogenicity of the O-specific polysaccharide (O-SP) moiety of LPS when coupled to a carrier protein may protect against bacterial pathogens. However, because of the toxic lipid A moiety and relatively high costs of O-SP isolation, LPS has not been a popular vaccine antigen until recently.

Areas covered

In this review, we discuss the rationales for developing LPS-based glycoconjugate vaccines, principles of glycoconjugate-induced immunity, and highlight the recent developments and challenges faced by LPS-based glycoconjugate vaccines.

Expert opinion

Advances in LPS harvesting, LPS chemical synthesis, and newer carrier proteins in the past decade have propelled LPS-based glycoconjugate vaccines toward further development, through to clinical evaluation. The development of LPS-based glycoconjugates offers a new horizon for vaccine prevention of Gram-negative bacterial infection.



中文翻译:

基于脂多糖的糖结合疫苗的最新进展

摘要

介绍

由于抗菌素耐药性,致病性革兰氏阴性菌引起的公共卫生负担日益突出。表面碳水化合物是革兰氏阴性菌疫苗的潜在抗原。当与载体蛋白偶联时,LPS 的 O 特异性多糖 (O-SP) 部分增强的免疫原性可以防止细菌病原体。然而,由于有毒的脂质 A 部分和 O-SP 分离的成本相对较高,LPS 直到最近才成为流行的疫苗抗原。

涵盖的领域

在这篇综述中,我们讨论了开发基于 LPS 的糖缀合物疫苗的基本原理、糖缀合物诱导免疫的原理,并强调了基于 LPS 的糖缀合物疫苗的最新发展和面临的挑战。

专家意见

在过去十年中,LPS 收获、LPS 化学合成和更新的载体蛋白方面的进展推动了基于 LPS 的糖缀合物疫苗的进一步开发,直至临床评估。基于 LPS 的糖缀合物的开发为革兰氏阴性细菌感染的疫苗预防提供了新的视野。

更新日期:2021-12-13
down
wechat
bug